Jianliang Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianliang Sun has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
Weiping Lei
Department of Anesthesiology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China
15 shared publicationsYaqin Huang
Department of Anesthesiology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China
14 shared publications- Ren-Shan Ge
The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University
8 shared publications Xinlei Lu
Department of Anesthesiology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, People’s Republic of China
7 shared publicationsJiahong Shen
Department of Anesthesiology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, People’s Republic of China
6 shared publicationsYe Xuan
The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China
5 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Effect of Oliceridine Fumarate for Patient-Controlled Intravenous Analgesia on Gastrointestinal Function in Laparoscopic Radical Gastrectomy Surgery: A Randomized, Double-Blind, Controlled Trial
Background: Postoperative ileus and opioid-related side effects are major barriers to recovery following laparoscopic gastrectomy. Oliceridine, a novel G-protein-biased μ-opioid receptor agonist, aims to offer effective analgesia with fewer adverse effects. This study evaluated the efficacy of oliceridine for patient-controlled intravenous analgesia (PCIA) on gastrointestinal (GI) recovery and analgesic outcomes. Methods: This single-center, prospective, randomized, double-blind, controlled trial enrolled 106 patients undergoing elective laparoscopic radical gastrectomy. Participants were randomized to receive either sufentanil (Group S, 1.5 μg/kg) or oliceridine (Group O, 0.35 mg/kg) for PCIA. The primary outcome was time to first flatus. Secondary outcomes included time to first defecation, I-FEED scores, Visual Analog Scale (VAS) scores, Richmond Agitation-Sedation Scale (RASS) scores, incidence of adverse events, and postoperative length of stay (LOS). Results: A total of 96 patients were included in the final analysis. Both groups demonstrated comparable analgesic efficacy, with no significant differences in VAS scores over 48 hours. However, the oliceridine group exhibited significantly faster GI recovery, including shorter times to first flatus (52.9 vs 59.2 hours) and first defecation (82.0 vs 93.0 hours). Patients in the oliceridine group also had lower I-FEED scores and resumed oral intake significantly faster. Oliceridine significantly reduced the incidence of nausea (10.2% vs 25.5%) and vomiting (4.1% vs 21.3%) compared to sufentanil. This group also demonstrated a calmer emergence profile, earlier first ambulation, and a significantly shorter postoperative LOS [11 (10, 12) vs 12 (10, 14) days]. No respiratory depression was observed in either cohort. Conclusion: In patients undergoing laparoscopic radical gastrectomy, oliceridine-based PCIA provides analgesic efficacy comparable to sufentanil but significantly accelerates gastrointestinal function recovery, improves emergence quality, reduces the incidence of postoperative nausea and vomiting, and shortens hospital stay. It represents a valuable analgesic strategy for Enhanced Recovery After Surgery (ERAS) protocols. Trial Registration: Chinese Clinical Trial Registry. Identifier: ChiCTR2500095364.
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-13
Open AccessEffect of Oliceridine Fumarate for Patient-Controlled Intravenous Analgesia on Gastrointestinal Function in Laparoscopic Radical Gastrectomy Surgery: A Randomized, Double-Blind, Controlled Trial
Background: Postoperative ileus and opioid-related side effects are major barriers to recovery following laparoscopic gastrectomy. Oliceridine, a novel G-protein-biased μ-opioid receptor agonist, aims to offer effective analgesia with fewer adverse effects. This study evaluated the efficacy of oliceridine for patient-controlled intravenous analgesia (PCIA) on gastrointestinal (GI) recovery and analgesic outcomes. Methods: This single-center, prospective, randomized, double-blind, controlled trial enrolled 106 patients undergoing elective laparoscopic radical gastrectomy. Participants were randomized to receive either sufentanil (Group S, 1.5 μg/kg) or oliceridine (Group O, 0.35 mg/kg) for PCIA. The primary outcome was time to first flatus. Secondary outcomes included time to first defecation, I-FEED scores, Visual Analog Scale (VAS) scores, Richmond Agitation-Sedation Scale (RASS) scores, incidence of adverse events, and postoperative length of stay (LOS). Results: A total of 96 patients were included in the final analysis. Both groups demonstrated comparable analgesic efficacy, with no significant differences in VAS scores over 48 hours. However, the oliceridine group exhibited significantly faster GI recovery, including shorter times to first flatus (52.9 vs 59.2 hours) and first defecation (82.0 vs 93.0 hours). Patients in the oliceridine group also had lower I-FEED scores and resumed oral intake significantly faster. Oliceridine significantly reduced the incidence of nausea (10.2% vs 25.5%) and vomiting (4.1% vs 21.3%) compared to sufentanil. This group also demonstrated a calmer emergence profile, earlier first ambulation, and a significantly shorter postoperative LOS [11 (10, 12) vs 12 (10, 14) days]. No respiratory depression was observed in either cohort. Conclusion: In patients undergoing laparoscopic radical gastrectomy, oliceridine-based PCIA provides analgesic efficacy comparable to sufentanil but significantly accelerates gastrointestinal function recovery, improves emergence quality, reduces the incidence of postoperative nausea and vomiting, and shortens hospital stay. It represents a valuable analgesic strategy for Enhanced Recovery After Surgery (ERAS) protocols. Trial Registration: Chinese Clinical Trial Registry. Identifier: ChiCTR2500095364.
- Open Access
- 12 March 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 199, 112786
Mri-based assessment of cervical muscle morphology in women with disc herniation: A retrospective case-control study
- 12 March 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 199, 112786
Open AccessMri-based assessment of cervical muscle morphology in women with disc herniation: A retrospective case-control study
- Open Access
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17
Estimated preventive dose of racemic ketamine for shivering and pruritus prophylaxis in cesarean delivery: a Monte Carlo simulation guided network meta-analysis
Background: The use of ketamine and esketamine in cesarean delivery is limited by their dose-dependent adverse effects. This study aimed to precisely quantify the dose-response relationships for the prevention of shivering and pruritus and to determine the associated risk of neuropsychiatric side effects, thereby defining its therapeutic window. Methods: A systematic review and network meta-analysis were conducted. We searched databases for randomized controlled trials (RCTs) evaluating a single intravenous bolus of ketamine or esketamine during cesarean delivery under neuraxial anesthesia. Study quality was assessed using the Cochrane RoB 2 tool. We integrated traditional and network meta-analysis with logistic regression, Monte Carlo simulation, and polynomial regression to establish continuous dose-response models and calculate key dose parameters (ED 50 , ED 95 ). Results: 25 studies(3,842 participants) were included. The ED 50 for preventing pruritus and shivering were 0.122 mg/kg (95% CI, 0.087–0.164) and 0.329 mg/kg (95% CI, 0.260–0.412), respectively. However, at doses of 0.273 mg/kg (ED 50 ) and 0.761 mg/kg (ED 95 ), 50% and 95% of parturients, respectively, experienced subjective side effects. Conclusion: The benefits of low-dose ketamine (≈0.12 mg/kg) for pruritus prophylaxis clearly outweigh its risks. In contrast, the dose required for shivering prevention (≈0.33 mg/kg) falls within the range where side effects become common, resulting in a narrow therapeutic window. This study provides critical dose-finding evidence for individualized, goal-directed use of ketamine in cesarean delivery. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251073122 , identifier CRD420251073122.
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17
Open AccessEstimated preventive dose of racemic ketamine for shivering and pruritus prophylaxis in cesarean delivery: a Monte Carlo simulation guided network meta-analysis
Background: The use of ketamine and esketamine in cesarean delivery is limited by their dose-dependent adverse effects. This study aimed to precisely quantify the dose-response relationships for the prevention of shivering and pruritus and to determine the associated risk of neuropsychiatric side effects, thereby defining its therapeutic window. Methods: A systematic review and network meta-analysis were conducted. We searched databases for randomized controlled trials (RCTs) evaluating a single intravenous bolus of ketamine or esketamine during cesarean delivery under neuraxial anesthesia. Study quality was assessed using the Cochrane RoB 2 tool. We integrated traditional and network meta-analysis with logistic regression, Monte Carlo simulation, and polynomial regression to establish continuous dose-response models and calculate key dose parameters (ED 50 , ED 95 ). Results: 25 studies(3,842 participants) were included. The ED 50 for preventing pruritus and shivering were 0.122 mg/kg (95% CI, 0.087–0.164) and 0.329 mg/kg (95% CI, 0.260–0.412), respectively. However, at doses of 0.273 mg/kg (ED 50 ) and 0.761 mg/kg (ED 95 ), 50% and 95% of parturients, respectively, experienced subjective side effects. Conclusion: The benefits of low-dose ketamine (≈0.12 mg/kg) for pruritus prophylaxis clearly outweigh its risks. In contrast, the dose required for shivering prevention (≈0.33 mg/kg) falls within the range where side effects become common, resulting in a narrow therapeutic window. This study provides critical dose-finding evidence for individualized, goal-directed use of ketamine in cesarean delivery. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251073122 , identifier CRD420251073122.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 10301-10302
Esketamine for Postoperative Depressive Symptoms: Considerations for Broader Perioperative Practice [Response to Letter]
Response to Letter in regards to Esketamine for Postoperative Depressive Symptoms: Considerations for Broader Perioperative Practice [Letter]
- 1 November 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 10301-10302
Open AccessEsketamine for Postoperative Depressive Symptoms: Considerations for Broader Perioperative Practice [Response to Letter]
Response to Letter in regards to Esketamine for Postoperative Depressive Symptoms: Considerations for Broader Perioperative Practice [Letter]
- Open Access
- 13 October 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 490
Feasibility and safety evaluation of remimazolam in geriatric patients during bronchoscopy: a single-centre randomized controlled trial
Fiberoptic bronchoscopy has developed rapidly as a routine test, especially it played an important role during the COVID-19. The suitable options for moderate sedation medications is necessary. The present study aimed to observation the feasibility and safety of remimazolam in geriatric patients undergoing fiberoptic bronchoscopy. This study is a single-center, randomized, parallel controlled trial conducted on patients undergoing fiberoptic bronchoscopy at the Hangzhou First People's Hospital, School of Medicine, Westlake University. A total of 105 geriatric patients undergoing fiberoptic bronchoscopy were divided into 3 groups (n=35) randomly. Group A (remimazolam + fentanyl + local anesthesia); Group B (midazolam + fentanyl + local anesthesia); Group C (local anesthesia).The primary outcomes include all patients' vital signs(Heart rate,non-invasive blood pressure,saturation of pulse oximetry,end-tidal carbon dioxide, bispectral index, respiratory rate), Modified Observer's Alertness/Sedatio and the rate of adverse events. Secondary outcomes are onset time of the drug, operation time , recovery time, operator and patient's satisfaction. This study enrolled a total of 105 patients, among them 97 were actually included in the statistics(34 in group A, 30 in group B, and 33 in group C). Compared with group C, the vital signs in group A and B are more stable at T1, T2, T3, and T4 times(P<0.05), the frequency of hypertension in group A and group B was significantly lower (P<0.05). Compared with group B, the onset time and recovery time of group A were shortened (both P<0.05). The satisfaction levels of both patients and operators in group A and group B were higher than those in group C. (P<0.05). In our study, we found that an intravenous injection of remimazolam at 0.2 mg/kg, combined with fentanyl at 0.5 μg/kg for sedation, along with local anesthesia of the pharynx and tracheal mucosa, and supplemental anesthesia with fentanyl 25 μg every 5 to 10 minutes if necessary, is effective and safe for geriatric patients during fiberoptic bronchoscopy. This study was registered with the Chinese clinical trial registry. ChiCTR2100047459,the Registration Date is 2021/06/19.
- 13 October 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 490
Open AccessFeasibility and safety evaluation of remimazolam in geriatric patients during bronchoscopy: a single-centre randomized controlled trial
Fiberoptic bronchoscopy has developed rapidly as a routine test, especially it played an important role during the COVID-19. The suitable options for moderate sedation medications is necessary. The present study aimed to observation the feasibility and safety of remimazolam in geriatric patients undergoing fiberoptic bronchoscopy. This study is a single-center, randomized, parallel controlled trial conducted on patients undergoing fiberoptic bronchoscopy at the Hangzhou First People's Hospital, School of Medicine, Westlake University. A total of 105 geriatric patients undergoing fiberoptic bronchoscopy were divided into 3 groups (n=35) randomly. Group A (remimazolam + fentanyl + local anesthesia); Group B (midazolam + fentanyl + local anesthesia); Group C (local anesthesia).The primary outcomes include all patients' vital signs(Heart rate,non-invasive blood pressure,saturation of pulse oximetry,end-tidal carbon dioxide, bispectral index, respiratory rate), Modified Observer's Alertness/Sedatio and the rate of adverse events. Secondary outcomes are onset time of the drug, operation time , recovery time, operator and patient's satisfaction. This study enrolled a total of 105 patients, among them 97 were actually included in the statistics(34 in group A, 30 in group B, and 33 in group C). Compared with group C, the vital signs in group A and B are more stable at T1, T2, T3, and T4 times(P<0.05), the frequency of hypertension in group A and group B was significantly lower (P<0.05). Compared with group B, the onset time and recovery time of group A were shortened (both P<0.05). The satisfaction levels of both patients and operators in group A and group B were higher than those in group C. (P<0.05). In our study, we found that an intravenous injection of remimazolam at 0.2 mg/kg, combined with fentanyl at 0.5 μg/kg for sedation, along with local anesthesia of the pharynx and tracheal mucosa, and supplemental anesthesia with fentanyl 25 μg every 5 to 10 minutes if necessary, is effective and safe for geriatric patients during fiberoptic bronchoscopy. This study was registered with the Chinese clinical trial registry. ChiCTR2100047459,the Registration Date is 2021/06/19.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 9685-9695
Effects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on postoperative depressive symptoms in breast cancer patients. Methods: In this randomized, double-blind, controlled trial, 96 female patients aged 18– 65 years undergoing unilateral modified radical mastectomy were enrolled. Participants were randomly assigned to one of two groups. The esketamine group received 0.5 mg/kg and 0.25 mg/kg/h esketamine and the normal saline group received 5 mL and 0.25 mL/kg/h normal saline during anesthesia induction and maintenance, respectively. The primary outcome was the Hamilton Depression Rating Scale (HAMD-17) score on postoperative day 30 (POD-30). Secondary outcomes included HAMD-17 scores on POD 1 and 3; self-Rating Depression Scale (SDS) scores on POD 1, 3, and 30; serum levels of brain-derived neurotrophic factor (BDNF) and serotonin (5-hydroxytryptamine, 5-HT) after surgery; relative changes in heart rate (HR) and mean arterial pressure (MAP) before and after intubation; time to awakening; Visual Analog Scale (VAS) pain scores; and adverse events related to esketamine. Results: The HAMD-17 score on POD-30 was significantly lower in the esketamine group [3.00 (2.08– 4.10)] than in the normal saline group [5.00 (4.00– 6.20)]. Regarding secondary outcomes, HAMD-17 scores on POD 1 and 3 were significantly lower in the esketamine group. SDS scores on POD 1, 3, and 30 were also significantly lower in the esketamine group. Compared with the saline group, the esketamine group exhibited significantly higher postoperative levels of BDNF and serotonin. Additionally, VAS scores at 30 minutes after extubation were significantly lower in the esketamine group. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Perioperative continuous administration of esketamine reduces postoperative depression scores in patients undergoing breast cancer surgery. Trial Registration: Chinese Clinical Trial Registry. Identifier: ChiCTR2200061575.
- 1 October 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 9685-9695
Open AccessEffects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on postoperative depressive symptoms in breast cancer patients. Methods: In this randomized, double-blind, controlled trial, 96 female patients aged 18– 65 years undergoing unilateral modified radical mastectomy were enrolled. Participants were randomly assigned to one of two groups. The esketamine group received 0.5 mg/kg and 0.25 mg/kg/h esketamine and the normal saline group received 5 mL and 0.25 mL/kg/h normal saline during anesthesia induction and maintenance, respectively. The primary outcome was the Hamilton Depression Rating Scale (HAMD-17) score on postoperative day 30 (POD-30). Secondary outcomes included HAMD-17 scores on POD 1 and 3; self-Rating Depression Scale (SDS) scores on POD 1, 3, and 30; serum levels of brain-derived neurotrophic factor (BDNF) and serotonin (5-hydroxytryptamine, 5-HT) after surgery; relative changes in heart rate (HR) and mean arterial pressure (MAP) before and after intubation; time to awakening; Visual Analog Scale (VAS) pain scores; and adverse events related to esketamine. Results: The HAMD-17 score on POD-30 was significantly lower in the esketamine group [3.00 (2.08– 4.10)] than in the normal saline group [5.00 (4.00– 6.20)]. Regarding secondary outcomes, HAMD-17 scores on POD 1 and 3 were significantly lower in the esketamine group. SDS scores on POD 1, 3, and 30 were also significantly lower in the esketamine group. Compared with the saline group, the esketamine group exhibited significantly higher postoperative levels of BDNF and serotonin. Additionally, VAS scores at 30 minutes after extubation were significantly lower in the esketamine group. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Perioperative continuous administration of esketamine reduces postoperative depression scores in patients undergoing breast cancer surgery. Trial Registration: Chinese Clinical Trial Registry. Identifier: ChiCTR2200061575.
- Open Access
Efficacy and safety of liposomal bupivacaine versus ropivacaine with two adjuncts in serratus anterior plane block for video-assisted thoracoscopic surgery: a protocol for a single-centre, randomised, double-blinded trial
Introduction Ultrasound-guided serratus anterior plane block (SAPB) is commonly used for postoperative pain management in video-assisted thoracoscopic surgery (VATS). However, the choice of local anaesthetics for SAPB remains controversial. This study aims to compare the efficacy and safety of liposomal bupivacaine versus ropivacaine combined with two local anaesthetic adjuncts (dexamethasone and dexmedetomidine) for postoperative pain relief in VATS patients. Methods and analysis This is a single-centre, double-blinded, randomised controlled trial conducted at the Hangzhou First People’s Hospital Affiliated to Westlake University School of Medicine in Hangzhou, China. A total of 120 adult patients scheduled for VATS will be randomly assigned in a 1:1:1 ratio to one of the following three groups: liposomal bupivacaine (group L), ropivacaine combined with dexamethasone (group D) and ropivacaine combined with dexmedetomidine (group R). The primary outcome is the Numeric Rating Scale pain score at rest at 24, 48 and 72 hours postoperatively. Secondary outcomes include opioid consumption, adverse events, Quality of Recovery-15 scores, patient satisfaction and length of hospital stay. Ethics and dissemination The study was approved by the Ethics Committee of the Hangzhou First People’s Hospital Affiliated to Westlake University School of Medicine (approval number IIT-2024405-01) on 6 November 2024. The protocol was registered in the Chinese Clinical Trial Registry on 9 January 2025. The planned study period is from 1 January 2025 to 31 December 2027, with participant recruitment scheduled from 1 March 2025 to 31 December 2026. Recruitment has not yet started. All participants will provide written informed consent. The results will be disseminated through peer-reviewed journals and academic conferences. Trial registration number ChiCTR2500095609.
Open AccessEfficacy and safety of liposomal bupivacaine versus ropivacaine with two adjuncts in serratus anterior plane block for video-assisted thoracoscopic surgery: a protocol for a single-centre, randomised, double-blinded trial
Introduction Ultrasound-guided serratus anterior plane block (SAPB) is commonly used for postoperative pain management in video-assisted thoracoscopic surgery (VATS). However, the choice of local anaesthetics for SAPB remains controversial. This study aims to compare the efficacy and safety of liposomal bupivacaine versus ropivacaine combined with two local anaesthetic adjuncts (dexamethasone and dexmedetomidine) for postoperative pain relief in VATS patients. Methods and analysis This is a single-centre, double-blinded, randomised controlled trial conducted at the Hangzhou First People’s Hospital Affiliated to Westlake University School of Medicine in Hangzhou, China. A total of 120 adult patients scheduled for VATS will be randomly assigned in a 1:1:1 ratio to one of the following three groups: liposomal bupivacaine (group L), ropivacaine combined with dexamethasone (group D) and ropivacaine combined with dexmedetomidine (group R). The primary outcome is the Numeric Rating Scale pain score at rest at 24, 48 and 72 hours postoperatively. Secondary outcomes include opioid consumption, adverse events, Quality of Recovery-15 scores, patient satisfaction and length of hospital stay. Ethics and dissemination The study was approved by the Ethics Committee of the Hangzhou First People’s Hospital Affiliated to Westlake University School of Medicine (approval number IIT-2024405-01) on 6 November 2024. The protocol was registered in the Chinese Clinical Trial Registry on 9 January 2025. The planned study period is from 1 January 2025 to 31 December 2027, with participant recruitment scheduled from 1 March 2025 to 31 December 2026. Recruitment has not yet started. All participants will provide written informed consent. The results will be disseminated through peer-reviewed journals and academic conferences. Trial registration number ChiCTR2500095609.
- Open Access
- 15 September 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (11) , 4703-4710
Comparative evaluation of large language models in delivering guideline-compliant recommendations for topical NSAID use in musculoskeletal pain: a multidimensional analysis
Introduction While large language models (LLMs) are increasingly used in clinical decision support, their adherence to evidence-based guidelines—particularly for musculoskeletal pain management—remains understudied. Methods Four LLMs (DeepSeek-R1, ChatGPT-4o, Gemini, Grok-3) were evaluated on their responses to topical NSAID use for musculoskeletal pain through: assessments of response quality (accuracy, over-conclusiveness, supplementary information, and incompleteness), standardized readability metrics (Flesch Reading Ease, Flesch-Kincaid Grade Level), and the PEMAT-P tool to quantify actionability. Results The four LLMs showed significant variability in accuracy (ANOVA p = 0.045), with Gemini scoring highest (8.33 ± 0.77) and DeepSeek-R1 lowest (7.72 ± 1.52) and in over-conclusiveness (ANOVA p = 0.025), with Grok-3 scoring lowest (4.56 ± 1.42) and ChatGPT-4o highest 6.72 ± 1.49). ChatGPT-4o provided the most supplementary content (6.94 ± 2.29, p = 0.106) and DeepSeek-R1 had the highest incompleteness (5.00 ± 2.52, p = 0.261). All models exceeded recommended readability thresholds (9th–10th grade level), and none met the actionability standard (≤ 33.5%). Conclusions LLMs demonstrate potential as clinical aids. The comprehensive performance of Gemini and Grok is relatively favorable, yet their readability and actionability remain unsatisfactory. Future development should integrate clinician feedback and real-world validation to ensure safety. Human oversight and targeted AI training are critical for safe implementation. Key Points • The study reveals significant differences in accuracy among LLMs, highlighting inconsistencies in clinical decision support. • While all models generated readable text, the complexity remained high, potentially limiting accessibility for some patients. • Glucocorticoid use for patients in remission was more strongly associated with impaired physical function in patients aged 75–84 than in patients aged 55–74 years. • Over-conclusiveness and incomplete adherence to evidence-based guidelines underscore the necessity for human oversight and targeted AI training in clinical applications.
- 15 September 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (11) , 4703-4710
Open AccessComparative evaluation of large language models in delivering guideline-compliant recommendations for topical NSAID use in musculoskeletal pain: a multidimensional analysis
Introduction While large language models (LLMs) are increasingly used in clinical decision support, their adherence to evidence-based guidelines—particularly for musculoskeletal pain management—remains understudied. Methods Four LLMs (DeepSeek-R1, ChatGPT-4o, Gemini, Grok-3) were evaluated on their responses to topical NSAID use for musculoskeletal pain through: assessments of response quality (accuracy, over-conclusiveness, supplementary information, and incompleteness), standardized readability metrics (Flesch Reading Ease, Flesch-Kincaid Grade Level), and the PEMAT-P tool to quantify actionability. Results The four LLMs showed significant variability in accuracy (ANOVA p = 0.045), with Gemini scoring highest (8.33 ± 0.77) and DeepSeek-R1 lowest (7.72 ± 1.52) and in over-conclusiveness (ANOVA p = 0.025), with Grok-3 scoring lowest (4.56 ± 1.42) and ChatGPT-4o highest 6.72 ± 1.49). ChatGPT-4o provided the most supplementary content (6.94 ± 2.29, p = 0.106) and DeepSeek-R1 had the highest incompleteness (5.00 ± 2.52, p = 0.261). All models exceeded recommended readability thresholds (9th–10th grade level), and none met the actionability standard (≤ 33.5%). Conclusions LLMs demonstrate potential as clinical aids. The comprehensive performance of Gemini and Grok is relatively favorable, yet their readability and actionability remain unsatisfactory. Future development should integrate clinician feedback and real-world validation to ensure safety. Human oversight and targeted AI training are critical for safe implementation. Key Points • The study reveals significant differences in accuracy among LLMs, highlighting inconsistencies in clinical decision support. • While all models generated readable text, the complexity remained high, potentially limiting accessibility for some patients. • Glucocorticoid use for patients in remission was more strongly associated with impaired physical function in patients aged 75–84 than in patients aged 55–74 years. • Over-conclusiveness and incomplete adherence to evidence-based guidelines underscore the necessity for human oversight and targeted AI training in clinical applications.
- Open Access
- 29 August 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 1-9
Effects of sufentanil combined with remifentanil on hemodynamics during induction and postoperative recovery quality in preschool children undergoing tonsillectomy and adenoidectomy
This study was designed to assess the effects of sufentanil combined with remifentanil on hemodynamics during induction and postoperative recovery quality in preschool children undergoing tonsillectomy and adenoidectomy. A total of 90 pediatric patients undergoing tonsillectomy and adenoidectomy under general anesthesia from October 2024 to March 2025 were included and randomly stratified to receive either Group R or Group S with equal probability. In Group R, anesthesia induction used sufentanil (0.2 µg/kg) combined with remifentanil (2 µg/kg), while only sufentanil (0.4 µg/kg) was used for anesthesia induction in Group S. The rest of the induction drugs were the same in both groups. After drug administration, patient vital signs, such as heart rate (HR) and mean arterial pressure (MAP), were monitored and recorded before induction (T0), immediately before tracheal intubation (T1), 1 min after tracheal intubation (T2), immediately after mouth gag placement (T3), immediately after extubation (T4), and 5 min post-extubation (T5), respectively. Additional outcomes of interest included anesthesia recovery time, an intubation condition score (Copenhagen Consensus Scale), emergence agitation (Pediatric Anesthesia Emergence Delirium [PAED] score), a postoperative pain assessment score (Face, Legs, Activity, Cry, and Consolability [FLACC] score), and adverse events. The primary outcome is postoperative awakening time (the time from the end of surgery to tracheal tube removal), which was shorter in Group R than in Group S, but this difference was not statistically significant (P > 0.05). The secondary outcomes include intraoperative hemodynamic parameters, intubation condition score (Copenhagen Consensus Scale), emergence agitation (Pediatric Anesthesia Emergence Delirium [PAED] score), a postoperative pain assessment score (Face, Legs, Activity, Cry, and Consolability [FLACC] score), and adverse events containing agitation during the awakening period, respiratory obstruction, nausea and vomiting, hypoxemia, and bradycardia. MAP was lower in Group R than in Group S at all time points, and was significantly lower at T3 (P < 0.05). HR was lower in Group R than in Group S at most time points, including being significantly lower at T2 (P < 0.05). No statistically significant differences were found between the two groups among the aforementioned secondary outcomes. Among preschool children undergoing tonsillectomy and adenoidectomy, the combination of sufentanil and remifentanil in general anesthesia ensured stable hemodynamics during induction and surgery, reduced the total dose of opioid anesthetics, shortened recovery time without compromising quality, and led to no significant adverse reactions. China Clinical Trial Center with registration number: ChiCTR2400090213,09/26/2024.
- 29 August 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 1-9
Open AccessEffects of sufentanil combined with remifentanil on hemodynamics during induction and postoperative recovery quality in preschool children undergoing tonsillectomy and adenoidectomy
This study was designed to assess the effects of sufentanil combined with remifentanil on hemodynamics during induction and postoperative recovery quality in preschool children undergoing tonsillectomy and adenoidectomy. A total of 90 pediatric patients undergoing tonsillectomy and adenoidectomy under general anesthesia from October 2024 to March 2025 were included and randomly stratified to receive either Group R or Group S with equal probability. In Group R, anesthesia induction used sufentanil (0.2 µg/kg) combined with remifentanil (2 µg/kg), while only sufentanil (0.4 µg/kg) was used for anesthesia induction in Group S. The rest of the induction drugs were the same in both groups. After drug administration, patient vital signs, such as heart rate (HR) and mean arterial pressure (MAP), were monitored and recorded before induction (T0), immediately before tracheal intubation (T1), 1 min after tracheal intubation (T2), immediately after mouth gag placement (T3), immediately after extubation (T4), and 5 min post-extubation (T5), respectively. Additional outcomes of interest included anesthesia recovery time, an intubation condition score (Copenhagen Consensus Scale), emergence agitation (Pediatric Anesthesia Emergence Delirium [PAED] score), a postoperative pain assessment score (Face, Legs, Activity, Cry, and Consolability [FLACC] score), and adverse events. The primary outcome is postoperative awakening time (the time from the end of surgery to tracheal tube removal), which was shorter in Group R than in Group S, but this difference was not statistically significant (P > 0.05). The secondary outcomes include intraoperative hemodynamic parameters, intubation condition score (Copenhagen Consensus Scale), emergence agitation (Pediatric Anesthesia Emergence Delirium [PAED] score), a postoperative pain assessment score (Face, Legs, Activity, Cry, and Consolability [FLACC] score), and adverse events containing agitation during the awakening period, respiratory obstruction, nausea and vomiting, hypoxemia, and bradycardia. MAP was lower in Group R than in Group S at all time points, and was significantly lower at T3 (P < 0.05). HR was lower in Group R than in Group S at most time points, including being significantly lower at T2 (P < 0.05). No statistically significant differences were found between the two groups among the aforementioned secondary outcomes. Among preschool children undergoing tonsillectomy and adenoidectomy, the combination of sufentanil and remifentanil in general anesthesia ensured stable hemodynamics during induction and surgery, reduced the total dose of opioid anesthetics, shortened recovery time without compromising quality, and led to no significant adverse reactions. China Clinical Trial Center with registration number: ChiCTR2400090213,09/26/2024.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7553-7569
Ciprofol Alleviates Depressive-Like Behaviors in CUMS Mice Through PPARα-Associated ERK/CREB Signaling Activation
Background: Depression is a complex neuropsychiatric disorder involving neuroinflammation, synaptic dysfunction, and neurotransmitter dysregulation. Recent studies have highlighted the therapeutic potential of short-acting anesthetics in the treatment of depression. Ciprofol, a novel intravenous anesthetic with rapid onset and recovery, shows promise, although its antidepressant mechanisms remain underexplored. Methods: We induced a depressive-like phenotype in mice using a 5-week chronic unpredictable mild stress (CUMS) protocol. Following model establishment, the mice received intraperitoneal injections of ciprofol (25 mg/kg) for 7 days. Behavioral assessments included the sucrose preference test (SPT), tail suspension test (TST), and forced swimming test (FST). To investigate neuroinflammation and microglial activation in the prefrontal cortex (PFC), we employed immunofluorescence staining, three-dimensional reconstruction, and quantitative real-time PCR (qRT-PCR). Synaptic structural changes were assessed using Western blot, three-dimensional reconstruction, and Golgi staining. Furthermore, transcriptome sequencing and Western blot were performed to elucidate the potential mechanisms underlying the antidepressant effects of ciprofol. Results: Ciprofol treatment alleviated CUMS-induced depressive behaviors, as evidenced by reduced immobility time and increased sucrose preference. Ciprofol suppressed PFC microglial activation and downregulated pro-inflammatory cytokines, while preserving synaptic integrity by inhibiting microglia-mediated synaptic phagocytosis. Mechanistic studies suggested that ciprofol’s antidepressant effect might be mediated by PPARα activation, which potentially triggers the ERK/CREB pathway, as indicated by transcriptome analysis and Western blot. Conclusion: Ciprofol can alleviate the depressive-like behaviors in CUMS mice by inhibiting the inflammatory response and reducing synaptic loss, and the mechanism may be related to the activation of the PPARα-mediated ERK/CREB pathway.
- 1 August 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7553-7569
Open AccessCiprofol Alleviates Depressive-Like Behaviors in CUMS Mice Through PPARα-Associated ERK/CREB Signaling Activation
Background: Depression is a complex neuropsychiatric disorder involving neuroinflammation, synaptic dysfunction, and neurotransmitter dysregulation. Recent studies have highlighted the therapeutic potential of short-acting anesthetics in the treatment of depression. Ciprofol, a novel intravenous anesthetic with rapid onset and recovery, shows promise, although its antidepressant mechanisms remain underexplored. Methods: We induced a depressive-like phenotype in mice using a 5-week chronic unpredictable mild stress (CUMS) protocol. Following model establishment, the mice received intraperitoneal injections of ciprofol (25 mg/kg) for 7 days. Behavioral assessments included the sucrose preference test (SPT), tail suspension test (TST), and forced swimming test (FST). To investigate neuroinflammation and microglial activation in the prefrontal cortex (PFC), we employed immunofluorescence staining, three-dimensional reconstruction, and quantitative real-time PCR (qRT-PCR). Synaptic structural changes were assessed using Western blot, three-dimensional reconstruction, and Golgi staining. Furthermore, transcriptome sequencing and Western blot were performed to elucidate the potential mechanisms underlying the antidepressant effects of ciprofol. Results: Ciprofol treatment alleviated CUMS-induced depressive behaviors, as evidenced by reduced immobility time and increased sucrose preference. Ciprofol suppressed PFC microglial activation and downregulated pro-inflammatory cytokines, while preserving synaptic integrity by inhibiting microglia-mediated synaptic phagocytosis. Mechanistic studies suggested that ciprofol’s antidepressant effect might be mediated by PPARα activation, which potentially triggers the ERK/CREB pathway, as indicated by transcriptome analysis and Western blot. Conclusion: Ciprofol can alleviate the depressive-like behaviors in CUMS mice by inhibiting the inflammatory response and reducing synaptic loss, and the mechanism may be related to the activation of the PPARα-mediated ERK/CREB pathway.